BioMarin Pharmaceutical, Inc.

BioMarin Pharmaceutical, Inc.

BioMarin Pharmaceutical, Inc.

Overview
Date Founded

1996

Headquarters

770 Lindaro Street, San Rafael, CA, 94901, USA

Type of Company

Public

Employees (Worldwide)

2,849

Industries

Biotechnology
Industrial Machinery & Manufacturing

Company Description

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

Contact Data
Trying to get in touch with decision makers at BioMarin Pharmaceutical, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer & President

Executive Vice President & Chief Financial Officer

Executive Vice President, General Counsel & Secretary

Executive Vice President & Chief Commercial Officer

Senior Vice President, Chief Compliance Officer

Chief Information Officer

Chief Medical Officer & Executive Vice President

Chief Accounting Officer, Senior Vice President-Finance & Controller

President of Global Manufacturing & Technical Operations

Benefit Plan Administrator

Board of Directors

Chief Executive Officer & President at BioMarin Pharmaceutical, Inc.

President at International Council of Ophthalmology Foundation

Former Executive Officers at Baxter International, Inc.

Principal at PureSight Advisory LLC

Professor & Executive Director-Personalized Health at University of Utah Health Sciences Center

Venture Partner at Pappas Capital LLC

Director, Clinical & Translational Research at Jonsson Comprehensive Cancer Center

Director at Reform Biologics LLC

Former Executive Vice President & Chief Financial Officer at Owens & Minor, Inc.

Co-Founder at Batu Biologics, Inc.

Paths to BioMarin Pharmaceutical, Inc.
Potential Connections via
Relationship Science
You
BioMarin Pharmaceutical, Inc.
Owners & Shareholders
Details Hidden

PRIMECAP invests primarily common stocks or securities with common stock characteristics, bonds and cash/cash equivalents. The firm utilizes fundamental research and bottom-up stock picking to construct portfolios. The main sources of information for research purposes include financial publications, inspections of corporate activities, research materials by others such as sell-side analysts, companies' annual reports and any related filings and press releases, meetings with executives of companies and their suppliers, competitors, customers, etc. All portfolios are built with the best ideas of each of the managers within the multi-manager investment process. PRIMECAP's investment strategy does not employ short sales or margin transactions, nor does it permit investments in derivatives or currency hedging. The firm follows an investment approach based on four key principles including commitment to fundamental research, long-term investment horizon, emphasis on individual decision-making and focus on value.

Details Hidden

Jennison Associates has expertise in a range of equity strategies across styles and market-caps, as well as fixed income strategies. The firm manages portfolios based on internal fundamental research, bottom-up security selection and a highly interactive investment process. Jennison Associates specializes in fundamental analysis, which involves attempting to gain insight into the future value of a company by studying company-specific and market-related quantitative (such as financial statements) and qualitative (such as quality of company management or products) information. Although portfolio managers ultimately make investment decisions for the portfolios they manage, they work closely with research analysts and other portfolio managers in a dynamic and continuous process of updating and debating investment ideas and company-specific convictions. They use quantitative tools to create and manage some of their customized equity portfolios and their quantitatively hedged portfolios.

Details Hidden

BBA primarily invests client assets in public and private securities and related assets and revenue streams of life sciences and health care companies and cash management investments. These securities include, but are not limited to: equity securities, including exchange-listed and over-the-counter securities; warrants; corporate debt securities, including convertible bonds; options contracts on securities; ETFS; and money market funds. BBA focuses on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. The firm adheres to a fundamentally-driven approach to life sciences investing. They typically take large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term.

Recent Transactions
Details Hidden

BioMarin Pharmaceutical, Inc. issued Common Stock

Details Hidden

BioMarin Pharmaceutical, Inc. purchases Prosensa Holding NV

Details Hidden

BioMarin Pharmaceutical, Inc. issued Common Stock

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onBioMarin Pharmaceutical, Inc. issued Common Stock

Auditor

Advised onBioMarin Pharmaceutical, Inc. issued Common Stock

Underwriter

Advised onBioMarin Pharmaceutical, Inc. issued Common Stock

Associate

Advised onBioMarin Pharmaceutical, Inc. issued Common Stock

Professional

Advised onBioMarin Pharmaceutical, Inc. issued Common Stock

Co-Chair, Capital Markets Practice

Advised onBioMarin Pharmaceutical, Inc. issued Common Stock

Advisors & Consultants
Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Consultant

Venture Partner at Clarus Ventures LLC

Advisor

Partner at Centerview Partners LLC

Clients

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Key Stats and Financials As of 2018
Market Capitalization
$14B
Total Enterprise Value
$14.8B
Earnings Per Share
$-0.44
Revenue
$1.5B
Net Profit
$-77.2M
EBITDA
$-63.1M
EBITDAMargin
-4.22%
Total Debt
$830M
Total Equity
$2.97B
Enterprise Value Sales
9.9x
TEVNet Income
-191.98x
Debt TEV
0.06x
Three Year Compounded Annual Growth Rate Of Revenue
19.74%
Five Year Compounded Annual Growth Rate Of Revenue
22.24%
Non-Profit Donations & Grants
Political Donations
$1,500
2014
$1,000
2014
$1,000
2010
Investors
Details Hidden

Partner at NEA Management Co. LLC

Suppliers
Brooks Automation, Inc. Appliances & Electronics | CHELMSFORD, MA

Brooks is a leading worldwide provider of automation, vacuum, and instrumentation solutions for multiple markets including semiconductor manufacturing, life sciences, and clean energy. Our technologies, engineering competencies, and breadth of global services provide customers speed to market, high uptime, and rapid response, which equate to superior value in their mission-critical environments. Since 1978, Brooks has been a leading partner to the global semiconductor manufacturing market. Through product development initiatives and strategic acquisition, we have expanded our reach to meet the needs of customers in the life sciences industry, analytical and research fields, and clean energy markets. When optimal productivity and high availability are factors for success, customers across the globe turn to Brooks. Brooks is a public company listed on the NASDAQ stock exchange under the symbol BRKS

Cambridge Cognition Holdings Plc Hospitals & Patient Services | Bottisham, CA

Cambridge Cognition Holdings Plc is a neuroscience digital health company. It focuses on developing brain health and biometrics software products. The firm operates through three segments: Software, Services and Hardware. The company's products include drug development, cognitive research and digital health. Cambridge Cognition Holdings was founded on September 12, 2012 and is headquartered in Cambridge, the United Kingdom.

Invitae Corp. Medical Support Services | San Francisco, California

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Competitors
Alnylam Pharmaceuticals, Inc. Pharmaceuticals - Cambridge, MA

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Moderna, Inc. Biotechnology - Cambridge, Massachusetts

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Roche Holding AG Pharmaceuticals - Basel, BS

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Awards & Honors
Rank #7
2014
Forbes - World's 100 Most Innovative Companies
Sponsored by Forbes Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by BioMarin Pharmaceutical, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of BioMarin Pharmaceutical, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and BioMarin Pharmaceutical, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/biomarin-pharmaceutical-inc-43750
  • https://relationshipscience.com/organization/biomarin-pharmaceutical-inc-43750